Table 1.

Reductions in incidence of invasive pneumococcal disease before introduction of 13-valent pneumococcal vaccine (2006–11)

	Incidence rate ratio (95% CI)	p value
Total
Infants	0·81 (0·74–0·88)	<0·0001
Children aged 1–4 years	0·86 (0·80–0·93)	<0·0001
Children aged 5–14 years	1·02 (0·93–1·11)	0·72
Individuals aged ≥15 years	0·92 (0·83–1·01)	0·084
Vaccine serotype disease
Infants	0·81 (0·72–0·90)	<0·0001
Children aged 1–4 years	0·92 (0·83–1·01)	0·068
Children aged 5–14 years	1·01 (0·90–1·13)	0·89
Individuals aged ≥15 years	0·89 (0·81–0·99)	0·030
Non-vaccine serotype disease
Infants	0·80 (0·75–0·86)	<0·0001
Children aged 1–4 years	0·78 (0·68–0·90)	0·0010
Children aged 5–14 years	1·04 (0·89–1·21)	0·62
Individuals aged ≥15 years	0·96 (0·85–1·08)	0·49

Data are n (%), unless otherwise specified. *χ² test (Mantel-Haenszel χ² where stratified) used for categorical covariates, unless fewer than five observations, where Fisher's exact test used. t test of means and rank-sum test of medians used for continuous covariates.